Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	189.22	36.42	16.98	91.94	20.75
Short-Term Investments	150.38	20.85	77.99	56.18	52.7
Cash & Cash Equivalents	339.6	57.26	94.97	148.12	73.45
Cash Growth	493.04%	-39.70%	-35.88%	101.66%	-1.43%
Receivables	0	0.38	0.82	0	0
Other Current Assets	1.93	4.62	3.11	1.67	1.06
Total Current Assets	341.53	62.26	98.89	149.79	74.51
Property, Plant & Equipment	0	6.65	8.36	9.87	7.11
Other Long-Term Assets	0.33	2.24	2.68	1.96	1.57
Total Long-Term Assets	0.33	8.89	11.04	11.83	8.68
Total Assets	341.86	71.14	109.93	161.62	83.18
Accounts Payable	0.9	0.68	3.32	2.25	3.15
Deferred Revenue	0	2.7	3.58	0	0
Current Debt	0	0.63	0.44	0.32	0.35
Other Current Liabilities	31.08	10.66	12.81	13.87	14.85
Total Current Liabilities	31.98	14.66	20.14	16.44	18.36
Long-Term Debt	0	4	4.61	5.13	4.71
Other Long-Term Liabilities	41.31	2.18	1.23	0.21	0.03
Total Long-Term Liabilities	41.31	6.18	5.84	5.34	4.74
Total Liabilities	73.29	20.84	25.99	21.79	23.1
Total Debt	0	4.63	5.04	5.45	5.06
Debt Growth	-	-8.23%	-7.42%	7.60%	-
Retained Earnings	-764.41	-425.62	-341.81	-276.01	-195.12
Comprehensive Income	0.3	-0.05	-0.02	0.01	0.05
Shareholders' Equity	184.02	50.31	83.94	139.83	60.08
Net Cash / Debt	339.6	52.64	89.92	142.67	68.39
Net Cash / Debt Growth	545.20%	-41.47%	-36.97%	108.62%	-8.22%
Net Cash Per Share	49.24	15.61	34.19	66.83	53.51
Working Capital	309.55	47.6	78.75	133.35	56.15
Book Value Per Share	26.68	14.92	31.92	65.50	47.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).